We bring innovative treatments to patients by advancing new therapies, expanding our existing products into new indications and geographies where they can address unmet medical need, and generating real-world evidence to strengthen understanding of their use in practice.
Our R&D focuses on late-stage development in Haematology and Immunology, where our pipeline and pre-market assets have the potential to create meaningful value for patients and the company.
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Here we present our most recent press releases, stories, news articles, and images.
Find out more about our business and financial performance.
Every day, we work actively to find better ways to understand and meet patient needs.